Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

Compare

359 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNTH Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Dianthus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNTH Stock 12 Month Forecast

Average Price Target

$49.25

▲(102.42% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is $49.25 with a high forecast of $92.00 and a low forecast of $21.00. The average price target represents a 102.42% change from the last price of $24.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","54":"$54","93":"$93","34.5":"$34.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$92.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,34.5,54,73.5,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.59,26.083076923076923,31.576153846153844,37.06923076923077,42.56230769230769,48.05538461538461,53.54846153846154,59.041538461538465,64.53461538461538,70.0276923076923,75.52076923076923,81.01384615384615,86.50692307692307,{"y":92,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.59,22.794615384615383,24.99923076923077,27.203846153846154,29.408461538461538,31.61307692307692,33.817692307692305,36.02230769230769,38.22692307692307,40.43153846153846,42.636153846153846,44.840769230769226,47.04538461538461,{"y":49.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.59,20.62153846153846,20.653076923076924,20.684615384615384,20.716153846153848,20.747692307692308,20.779230769230768,20.810769230769232,20.842307692307692,20.873846153846152,20.905384615384616,20.936923076923076,20.96846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$92.00

Average Price Target$49.25

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rami Katkhuda

LifeSci Capital

$45

Buy

84.96%

Upside

Reiterated

08/26/25

Promising Outlook and Strategic Positioning Make Dianthus Therapeutics a BuyThis morning, Regeneron (Nasdaq: REGN) announced that the Phase III NIMBLE trial met its primary and key secondary endpoints with cemdisiran monotherapy (an-C5 siRNA) as well as a cemdisiran+pozelimab (an-C5 mAb) combinaon versus placebo in AChR+ gMG paents.

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

08/22/25

Cantor Fitzgerald Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Dianthus Therapeutics (NASDAQ: DNTH).

Laura Chico

Wedbush

$34→$42

Buy

72.63%

Upside

Reiterated

08/21/25

Dianthus price target raised to $42 from $34 at WedbushDianthus price target raised to $42 from $34 at Wedbush

Gavin Clark-Gartner

Evercore ISI

$50

Buy

105.51%

Upside

Reiterated

08/15/25

Dianthus Therapeutics (DNTH) Gets a Buy from Evercore ISI

Yatin Suneja

Guggenheim

$92

Buy

278.13%

Upside

Reiterated

08/14/25

Dianthus Therapeutics (DNTH) Receives a Buy from Guggenheim

Dex Genotek

TR | OpenAI - 4o

$19→$21

Hold

-13.69%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Swayampakula Ramakanth

H.C. Wainwright

$40

Buy

64.41%

Upside

Reiterated

08/11/25

Promising Clinical Developments and Financial Stability Drive Buy Recommendation for Dianthus Therapeutics

Trevor Allred

Oppenheimer

$52

Buy

113.73%

Upside

Reiterated

08/08/25

Oppenheimer Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

08/07/25

Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating

Myles Minter

William Blair

―

Buy

―

Reiterated

08/07/25

Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart's Potential in gMG

Alex Thompson CFA

Stifel Nicolaus

$52

Buy

113.73%

Upside

Reiterated

07/14/25

Dianthus Therapeutics (DNTH) Gets a Buy from Stifel Nicolaus

Joel Beatty

Robert W. Baird

$58→$50

Buy

105.51%

Upside

Reiterated

05/13/25

Dianthus price target lowered to $50 from $58 at BairdDianthus price target lowered to $50 from $58 at Baird

Sean Lee

Citi

$40

Buy

64.41%

Upside

Reiterated

03/11/25

Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rami Katkhuda

LifeSci Capital

$45

Buy

84.96%

Upside

Reiterated

08/26/25

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

08/22/25

Cantor Fitzgerald Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Dianthus Therapeutics (NASDAQ: DNTH).

Laura Chico

Wedbush

$34→$42

Buy

72.63%

Upside

Reiterated

08/21/25

Dianthus price target raised to $42 from $34 at WedbushDianthus price target raised to $42 from $34 at Wedbush

Gavin Clark-Gartner

Evercore ISI

$50

Buy

105.51%

Upside

Reiterated

08/15/25

Dianthus Therapeutics (DNTH) Gets a Buy from Evercore ISI

Yatin Suneja

Guggenheim

$92

Buy

278.13%

Upside

Reiterated

08/14/25

Dianthus Therapeutics (DNTH) Receives a Buy from Guggenheim

Dex Genotek

TR | OpenAI - 4o

$19→$21

Hold

-13.69%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Swayampakula Ramakanth

H.C. Wainwright

$40

Buy

64.41%

Upside

Reiterated

08/11/25

Promising Clinical Developments and Financial Stability Drive Buy Recommendation for Dianthus Therapeutics

Trevor Allred

Oppenheimer

$52

Buy

113.73%

Upside

Reiterated

08/08/25

Oppenheimer Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

08/07/25

Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating

Myles Minter

William Blair

―

Buy

―

Reiterated

08/07/25

Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart's Potential in gMG

Alex Thompson CFA

Stifel Nicolaus

$52

Buy

113.73%

Upside

Reiterated

07/14/25

Dianthus Therapeutics (DNTH) Gets a Buy from Stifel Nicolaus

Joel Beatty

Robert W. Baird

$58→$50

Buy

105.51%

Upside

Reiterated

05/13/25

Dianthus price target lowered to $50 from $58 at BairdDianthus price target lowered to $50 from $58 at Baird

Sean Lee

Citi

$40

Buy

64.41%

Upside

Reiterated

03/11/25

Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

1 Month

xxx

Success Rate

5/7 ratings generated profit

Average Return

+9.40%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +9.40% per trade.

3 Months

xxx

Success Rate

6/7 ratings generated profit

Average Return

+26.64%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +26.64% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

6/6 ratings generated profit

Average Return

+12.83%

reiterated a buy rating 22 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +12.83% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+12.83%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +12.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNTH Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNTH has received 25 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. DNTH average Analyst price target in the past 3 months is 49.25.

Each month's total comprises the sum of three months' worth of ratings.

DNTH Financial Forecast

DNTH Earnings Forecast

Next quarter’s earnings estimate for DNTH is -$0.90 with a range of -$1.03 to -$0.71. The previous quarter’s EPS was -$0.88. DNTH beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year DNTH has Outperformed its overall industry.

DNTH Sales Forecast

Next quarter’s sales forecast for DNTH is $640.00K with a range of $0.00 to $2.28M. The previous quarter’s sales results were $193.00K. DNTH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year DNTH has Outperformed its overall industry.

DNTH Stock Forecast FAQ

What is DNTH’s average 12-month price target, according to analysts?

Based on analyst ratings, Dianthus Therapeutics, Inc.’s 12-month average price target is 49.25.

What is DNTH’s upside potential, based on the analysts’ average price target?

Dianthus Therapeutics, Inc. has 102.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNTH a Buy, Sell or Hold?

Dianthus Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Dianthus Therapeutics, Inc.’s price target?

The average price target for Dianthus Therapeutics, Inc. is 49.25. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $92.00 ,the lowest forecast is $21.00. The average price target represents 102.42% Increase from the current price of $24.33.

What do analysts say about Dianthus Therapeutics, Inc.?

Dianthus Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of DNTH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

DNTH Analyst Ratings

DNTH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dianthus Therapeutics

DNTH Analyst Recommendation Trends

DNTH Financial Forecast

DNTH Earnings Forecast

DNTH Sales Forecast

DNTH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts